# Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
Canonical URL: https://biopharmsignal.com/news/PLRX/pliant-therapeutics-announces-presentation-of-updated-data-from-the-phase-1-trial-of-pln-101095-in-patients-with-ici-refractory-solid-tumors-at-the-2026-aacr-annual-meeting
Ticker: PLRX
Company: Pliant Therapeutics
Source: Pliant Therapeutics
Published: 2026-04-18 17:31 EST
Original Source URL: https://ir.pliantrx.com
## Summary

Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months  Data highlighted in oral presentation at AACR’s Clinical Trials Mini Symposium Phase 1b indication expansion trial is enrolling SOUTH SAN FRANCISCO, Calif.,

## Article Body
Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months  Data highlighted in oral presentation at AACR’s Clinical Trials Mini Symposium Phase 1b indication expansion trial is enrolling SOUTH SAN FRANCISCO, Calif.,
## Recent Company News
- 2026-05-21 21:30 EST — [Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting](https://biopharmsignal.com/news/PLRX/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting) — Source: Pliant Therapeutics
- 2026-05-11 20:05 EST — [Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-first-quarter-2026-financial-results) — Source: Pliant Therapeutics
- 2026-05-06 12:30 EST — [Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference](https://biopharmsignal.com/news/PLRX/pliant-therapeutics-to-participate-in-the-rbc-capital-markets-global-healthcare-conference) — Source: Pliant Therapeutics
- 2026-04-30 12:30 EST — [Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors](https://biopharmsignal.com/news/PLRX/pliant-therapeutics-announces-first-patient-dosed-in-fortify-the-phase-1b-indication-expansion-trial-evaluating-pln-101095-in-patients-with-ici-refractory-solid-tumors) — Source: Pliant Therapeutics
- 2026-04-18 17:31 EST — [Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting](https://biopharmsignal.com/news/PLRX/pliant-therapeutics-announces-presentation-of-updated-data-from-the-phase-1-trial-of-pln-101095-in-patients-with-ici-refractory-solid-tumors-at-the-2026-aacr-annual-meeting) — Source: Pliant Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)